NTRK fusions are oncogenic drivers regardless of the tissue of origin, and first-generation TRK tyrosine kinase inhibitors (larotrectinib, entrectinib, or ropotrectinib) have demonstrated very promising antitumor efficacies in both adult and pediatric patients with NTRK fusion-positive cancers [13–15]. The gene discussed is NTRK1; the disease is cancer.